AYTU
AYTU BIOPHARMA, INC
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$1.90
−4.04%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 57.6M | 57.6M | 66.4M | 65.2M | 107.4M |
| Cost of Revenue | 20.8M | 20.8M | 20.6M | 16.1M | 40.8M |
| Gross Profit | 36.8M | 36.8M | 45.8M | 49.1M | 66.6M |
| Operating Expenses | |||||
| R&D Expense | — | — | 1.3M | 2.8M | 4.1M |
| SG&A Expense | 42.6M | 42.6M | 38.3M | 42.0M | 70.1M |
| General & Admin Expense | 19.3M | 19.3M | 17.4M | 20.0M | 28.6M |
| Selling & Marketing Expense | 23.4M | 23.4M | 20.9M | 22.1M | 41.4M |
| Other Expenses | 2.5M | 2.5M | 14.0M | 5.8M | 9.5M |
| Total Operating Expenses | 45.1M | 45.1M | 53.7M | 50.6M | 83.7M |
| Cost and Expenses | 65.9M | 65.9M | 74.2M | 66.8M | 124.5M |
| Operating Income (EBIT) | (8.3M) | (8.3M) | (7.8M) | (1.6M) | (17.1M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 1.1M | (1.9M) | 3.7M | 4.8M | 5.0M |
| Net Interest Income | (1.9M) | (1.9M) | (3.7M) | (4.8M) | (5.0M) |
| Other Non-Op Income/Expense | (5.9M) | (5.9M) | (5.9M) | (8.8M) | 14.0K |
| Non-Operating Income (excl Interest) | 4.0M | 4.0M | 2.2M | 3.7M | (5.0M) |
| EBT (Pre-Tax Income) | (14.2M) | (14.2M) | (13.7M) | (10.4M) | (17.1M) |
| Income Tax Expense | (1.0K) | (21.0K) | 437.0K | 2.1M | — |
| Bottom Line | |||||
| Net Income | (14.3M) | (14.3M) | (13.6M) | (15.8M) | (17.1M) |
| Earnings from Cont. Ops | (14.3M) | (14.3M) | (14.2M) | (12.5M) | (17.1M) |
| Earnings from Discont. Ops | — | — | 620.0K | (3.3M) | — |
| Bottom Line Net Income | (17.7M) | (14.3M) | (13.6M) | (15.8M) | (17.1M) |
| Per Share | |||||
| Basic EPS | ($1.37) | ($1.16) | ($2.16) | ($2.86) | ($5.11) |
| Diluted EPS | ($1.66) | ($1.16) | ($2.16) | ($2.86) | ($5.11) |
| Revenue Per Share | $4.67 | $4.67 | $10.57 | $11.77 | $32.16 |
| Shares | |||||
| Basic Shares Outstanding | 12.3M | 12.3M | 6.3M | 5.5M | 3.3M |
| Diluted Shares Outstanding | 12.3M | 12.3M | 6.3M | 5.5M | 3.3M |
| Profitability Metrics | |||||
| EBITDA | (8.5M) | (4.4M) | (4.7M) | 1.4M | (3.3M) |
| D&A | 3.9M | 3.9M | 5.4M | 6.7M | 8.8M |
| EBIT | (12.3M) | (12.3M) | (10.0M) | (5.3M) | (12.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026